Canton Strategic Holdings Inc
CNTNNASDAQHealthcareBiotechnology
Previous close
$2.19
−$0.02 · -0.90%
CNTN company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
27
Expensive
Momentum
21
Weakening
Sentiment
53
Mixed
Risk resilience
28
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteCanton Strategic Holdings Inc., which was formerly known as Tharimmune, Inc. until its name change in February 2026, focuses on two primary areas. The company is committed to promoting the institutional integration of blockchain technology and fostering the digitization of financial markets, primarily by leveraging Canton Coin and offering support to the Canton network. In addition to its blockchain initiatives, the company is also deeply involved in pharmaceutical research and development. Its pipeline includes GV104, a buccal film technology designed to address respiratory and/or nervous system depression in military personnel and chemical incident responders, which has already finished its Phase 1 trial. Another significant project is GV023, an oral version of infliximab, engineered to resolve the key inconvenience of the standard intravenous treatment by eliminating the need for recurring infusions. Established in 2017, Canton Strategic Holdings Inc. is headquartered in Red Bank, New Jersey.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Mark Wendland
- Listed since
- Jan 12, 2022
- Employees
- 12
Market position
Day range
Current $2.19
52-week range
Current $2.19
- Open
- $2.15
- Previous close
- $2.21
- Volume
- 744.7K
- 0.89× average
- Average volume
- 832.93K
- Average daily volume
- Market cap
- 168.9M USD
- Beta
- 1.47
- Market reference 1
- 50-day average
- $2.3836
- -8.12% below average
- 200-day average
- $3.1312
- -30.06% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 80.08M USD
- P/E (TTM)
- -1.39×
- P/B (TTM)
- 1.04×
- P/S (TTM)
- 112.91×
- EV / EBITDA
- -1.9×
- Earnings yield
- -36.99%
- Free cash flow yield
- -96.49%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 100.00%
- Operating margin
- -3595.17%
- Net margin
- -6559.27%
- Return on equity
- -9.03%
- Return on assets
- -6.92%
- Return on invested capital
- -3.32%
Financial health
- Debt / equity
- 0×
- Current ratio
- 5.29×
- Altman Z-score
- 0.15
- Piotroski F-score
- 4 of 9
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 3.07M USD | 6.39M USD | 3.56M USD | 2.28M USD | 1.84M USD |
| Selling, general, and administrative | 17.03M USD | 6.04M USD | 5.9M USD | 4.6M USD | 1.37M USD |
| Operating expenses | 20.11M USD | 12.43M USD | 9.46M USD | 6.88M USD | 3.21M USD |
| Interest income | 41.41K USD | 249.91K USD | 152.63K USD | — | — |
| Interest expense | 28.35K USD | 13.68K USD | 16.51K USD | 1.59M USD | 831.28K USD |
| Depreciation and amortization | 24.83K USD | — | 152.63K USD | 228.49K USD | — |
| Operating income | −20.11M USD | −12.43M USD | −9.46M USD | −6.88M USD | −3.21M USD |
| Net income | −35.92M USD | −12.2M USD | −9.32M USD | −8.47M USD | −2.21M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 33%
- 2 beats, 4 misses, 0 met estimates
- Average EPS surprise
- -62.84%
- 6 comparable reports
- Latest EPS result
- 0.01
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
CNTN news
CNTN peers
ETFs holding CNTN
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI4.22M0.00%2.3T USD0.03%$378.24+0.44%
Vanguard Extended Market ETFVXF1.54M0.00%93.7B USD0.05%$245.53+0.82%
ARK Blockchain & Fintech Innovation ETFARKF862.03K0.11%700.8M USD0.75%$45.72+3.51%
Vanguard Russell 2000 ETFVTWO479.33K0.00%17.4B USD0.06%$121.25+0.74%
Vanguard Russell 2000 Value ETFVTWV77.35K0.01%1.4B USD0.06%$198.38+0.34%
Global X - Russell 2000 ETFRSSL46.09K—1.53B USD0.08%$117.49+0.86%
Vanguard Russell 3000 ETFVTHR10.84K0.00%6.1B USD0.06%$338.91+0.49%
ProShares - UltraPro Russell2000URTY3.95K0.00%340.71M USD1.08%$85.08+2.19%Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 4.22M
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
Vanguard Extended Market ETFVXF- Market value
- 1.54M
- Weight
- 0.00%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $245.53+0.82%
ARK Blockchain & Fintech Innovation ETFARKF- Market value
- 862.03K
- Weight
- 0.11%
- AUM
- 700.8M USD
- Expense ratio
- 0.75%
- Price / 1D
- $45.72+3.51%
Vanguard Russell 2000 ETFVTWO- Market value
- 479.33K
- Weight
- 0.00%
- AUM
- 17.4B USD
- Expense ratio
- 0.06%
- Price / 1D
- $121.25+0.74%
Vanguard Russell 2000 Value ETFVTWV- Market value
- 77.35K
- Weight
- 0.01%
- AUM
- 1.4B USD
- Expense ratio
- 0.06%
- Price / 1D
- $198.38+0.34%
Global X - Russell 2000 ETFRSSL- Market value
- 46.09K
- Weight
- —
- AUM
- 1.53B USD
- Expense ratio
- 0.08%
- Price / 1D
- $117.49+0.86%
Vanguard Russell 3000 ETFVTHR- Market value
- 10.84K
- Weight
- 0.00%
- AUM
- 6.1B USD
- Expense ratio
- 0.06%
- Price / 1D
- $338.91+0.49%
ProShares - UltraPro Russell2000URTY- Market value
- 3.95K
- Weight
- 0.00%
- AUM
- 340.71M USD
- Expense ratio
- 1.08%
- Price / 1D
- $85.08+2.19%
Continue in GoAI
Research CNTNresearch.disclaimer